Correction: VTX-PID as a novel recombinant immunoglobulin G–degrading enzyme (IdeS) for efficient AAV-based gene therapy in participants with neutralizing antibodies: results of the phase I first-in-human NAVIgATE study - Poll - MDSpire

Correction: VTX-PID as a novel recombinant immunoglobulin G–degrading enzyme (IdeS) for efficient AAV-based gene therapy in participants with neutralizing antibodies: results of the phase I first-in-human NAVIgATE study

  • By

  • Bernard Benichou

  • Rainard Fuhr

  • Elodie Vernadal

  • Sonia Valero

  • Blanche Tamarit

  • Veronica Ferrer

  • Gloria Gonzalez-Aseguinolaza

  • Anne Douar

  • Marc Froissart

  • Annelise Brossel

  • Simone Floettmann

  • Francesca Del Bene

  • Céline Bouquet

  • Jean-Philippe Combal

  • June 17, 2026

  • 0 min

Share

Original Source(s)

Correction: VTX-PID as a novel recombinant immunoglobulin G–degrading enzyme (IdeS) for efficient AAV-based gene therapy in participants with neutralizing antibodies: results of the phase I first-in-human NAVIgATE study

  • by Bernard Benichou, Rainard Fuhr, Elodie Vernadal, Sonia Valero, Blanche Tamarit, Veronica Ferrer, Gloria Gonzalez-Aseguinolaza, Anne Douar, Marc Froissart, Annelise Brossel, Simone Floettmann, Francesca Del Bene, Céline Bouquet, Jean-Philippe Combal

  • June 17, 2026

Related Content

Development of bispecific antibodies with enhanced neutralization activity against tested SARS-CoV-2 Omicron subvariants

Digital epidemiology and public health surveillance: scientometric mapping of emerging technologies and challenges (2000–2025)

Local, State, and National Efforts That Support Influenza Surveillance—From the Ground Up